^
    Back
    Association details:
    Biomarker:BRAF T599
    Cancer:Ganglioglioma
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Cold Spring Harb Mol Case Stud
    Title:

    Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with BRAF p.T599dup mutation

    Published date:
    02/26/2021
    Excerpt:
    An adolescent female initially presented with blurred vision...Pathological examination showed a low-grade brain tumor: ganglioglioma...Subsequent genome sequencing of the tumor specimen revealed a BRAF p.T599dup mutation...The patient has been receiving dabrafenib plus trametinib for 15 months and continues to have stable disease as well as improved neurological symptoms.
    DOI:
    10.1101/mcs.a006023